Эффективность аллогенной трансплантации гемопоэтических стволовых клеток с миелоаблативным режимом и режимом кондиционирования со сниженной интенсивностью у детей и подростков с острым миелобластным лейкозом
Бондаренко Сергей Николаевич, Разумова Светлана Викторовна, Natalia V Stancheva et al. · Oncopediatrics · 2015
Introduction . Acute myeloid leukemia (AML), with a relatively rare occurrence, remains one of the most adverse prognostic variants of malignant diseases in children and adolescents. Aim . To evaluate the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in AML in children and adolescents depending on the disease status, conditioning regimen and source of transplant. Materials and methods . A total of 118 pediatric and adolescent patients with AML were included in the study. The median patients age was 12,5 (range 1–21) years, M/F distribution was from 58 (49%) to 60 (51%). The median follow-up period was 27 (range 2–120) months. Fourty two (36%) of the patients were in the 1st CR, 30 (25%) in the 2nd CR, 46 (39%) had active disease. All patients received allo-HSCT from related (n = 31; 26%) or unrelated (n = 87; 74%) donor. The stem cell source was bone marrow in 59 (50%) patients and PBSC in 59 (50%) patients. In 66 (56%) patients the myeloablative (MAC) and in 52 (44%) patients reduced-intensity (RIC) conditioning regimen was used. Acute GVHD prophylaxis consisted of cyclosporine A (n = 79; 67%) or tacrolimus (n = 39; 33%). Results . The 5-year OS in MAC and RIC allo-HSCT recipients was 65% (95% CI 45–85) and 80% (95% CI 59–99) (р = 0,4) if allo-HSCT was performed in the 1st CR, accordingly. In patients with 2nd CR it was 65% (95% CI 35–95) and 17% (95% CI 1–37) (р = 0,003), in patients withour remission 17% (95% CI 1–43) and 19% (95% CI 1–37) (р = 0,4), accordingly. MAC and RIC allo-HSCT recipients had relapses in 24% (95% CI 10–41) and 29% (95% CI 12–48) (р = 0,7) of cases, accordingly. In patients receiving MAC or RIC allo-HSCT in 1st or 2nd CR the relapse rate did not correlate with donor type (related or unrelated, p = 0,2 for MAC and p = 0,3 for RIC) or stem cell source (BM or PBSC, р = 0,9 for MAC and p = 0,4 for RIC). There was also no correlation between relapse rate and patient’s age: younger than 14 years 20% (95% CI 7–38) in MAC group and 33% in RIC group (95% CI 9–60) (р = 0,5); in patients of 14–21 years 29% in MAC (95% CI 5–59) and 27% (95% CI 5–56) (р = 0,9) in RIC group, accordingly. Discussion . The relapse rate was significantly lower in MAC allo-HSCT recipients with aGVHD Gr I–III compared to RIC allo-HSCT recipients (р = 0,05), although no such correlation was observed in patients with cGVHD (р = 0,2). RIC allo-HSCT was associated with significantly lower toxicity rate, while the infectious complications and GVHD (acute and chronic) rate was comparable for both MAC and RIC allo-HSCT recipients groups. The mortality rate did not correlate to age or conditioning regimen type. The most common death causes in RIC allo-HSCT recipients were disease progression (36%), infectious complications (21%) and aGVHD (43%). In MAC allo-HSCT recipients the most common death causes were disease progression (37%), infectious complications (30%), aGVHD (22%) and treatment related toxicity (11%). Conclusion . The efficacy of reduced intensity conditioning regimens is comparable with myeloablative regimen for allo-HSCT in children and adolescents with AML.
Cited by 4 works.